Plus Therapeutics Inc
PSTV0.535USD
-0.010-1.82%
Market hours （ET）Quotes delayed by 15 min
70.41MMarket Cap
LossP/E TTM
More Details of Plus Therapeutics Inc Company
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
Plus Therapeutics Inc Info
Ticker SymbolPSTV
Company namePlus Therapeutics Inc
IPO dateAug 09, 2000
CEODr. Marc H. Hedrick, M.D.
Number of employees21
Security typeOrdinary Share
Fiscal year-endAug 09
Address4200 Marathon Blvd.
CityAUSTIN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code78756
Phone17372557194
Websitehttp://www.plustherapeutics.com/
Ticker SymbolPSTV
IPO dateAug 09, 2000
CEODr. Marc H. Hedrick, M.D.
Company Executives of Plus Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
180.11K
+781.79%
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
139.33K
+375.08%
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Michael Stanley Rosol, Ph.D.
Dr. Michael Stanley Rosol, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
180.11K
+781.79%
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
139.33K
+375.08%
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2018
By BusinessUSD
Name
Revenue
Proportion
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
By RegionUSD
Name
Revenue
Proportion
Japan
2.06M
77.05%
Americas
293.00K
10.97%
EMEA
270.00K
10.11%
Asia Pacific
50.00K
1.87%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
Shareholding Stats
Updated: 15 hours ago
Updated: 15 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
S.H.N. Financial Investments Ltd
1.09%
Hedrick (Marc H)
0.13%
Lenk (Robert P)
0.10%
Jane Street Capital, L.L.C.
0.09%
UBS Financial Services, Inc.
0.06%
Other
98.53%
Shareholders
Shareholders
Proportion
S.H.N. Financial Investments Ltd
1.09%
Hedrick (Marc H)
0.13%
Lenk (Robert P)
0.10%
Jane Street Capital, L.L.C.
0.09%
UBS Financial Services, Inc.
0.06%
Other
98.53%
Shareholder Types
Shareholders
Proportion
Corporation
1.09%
Individual Investor
0.29%
Investment Advisor
0.12%
Research Firm
0.11%
Investment Advisor/Hedge Fund
0.04%
Hedge Fund
0.03%
Other
98.32%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
34
1.29M
5.50%
-596.16K
2025Q2
35
2.30M
3.80%
-2.38M
2025Q1
40
2.31M
11.85%
+1.40M
2024Q4
42
829.50K
14.07%
-98.90K
2024Q3
44
822.91K
13.96%
-122.82K
2024Q2
46
793.04K
13.90%
-131.21K
2024Q1
46
164.14K
3.77%
-119.25K
2023Q4
47
203.09K
4.50%
+1.47K
2023Q3
47
127.65K
2.90%
-110.39K
2023Q2
45
114.35K
4.03%
-124.09K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
S.H.N. Financial Investments Ltd
1.50M
1.51%
+614.55K
+69.40%
Aug 14, 2025
Hedrick (Marc H)
20.43K
0.02%
--
--
Jun 18, 2025
Lenk (Robert P)
139.33K
0.14%
+110.00K
+375.08%
Aug 22, 2025
Jane Street Capital, L.L.C.
117.45K
0.12%
+117.45K
--
Jun 30, 2025
UBS Financial Services, Inc.
87.64K
0.09%
+54.20K
+162.10%
Jun 30, 2025
Geode Capital Management, L.L.C.
51.18K
0.05%
-5.88K
-10.30%
Jun 30, 2025
Sims Andrew (John Hugh MacIntyre)
9.81K
0.01%
--
--
Jun 18, 2025
The Vanguard Group, Inc.
32.54K
0.03%
--
--
Jun 30, 2025
Goldman Sachs & Company, Inc.
26.75K
0.03%
+26.75K
--
Jun 30, 2025
Clowes (Howard)
26.50K
0.03%
--
--
Jun 18, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Date
Type
Ratio
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
